Company intelligence / Profile preview

EdgeWave

Boulder, Colorado, United Statesedge-wave.de ↗

Ownership: Private
Employees: ~110
Development stage: Other

Overview

Edgewise Therapeutics is advancing a pipeline of small molecule therapies for rare and severe muscle diseases. Its lead candidate, EDG-5506 (sevasemten), is in Phase III trials for Becker muscular dystrophy and has shown promise as a first-in-class fast skeletal myosin inhibitor. EDG-7500, targeting hypertrophic cardiomyopathy, is in Phase II development. The company’s approach leverages precision medicine to modulate key muscle proteins with the goal of addressing significant unmet needs in genetically defined muscle disorders

Therapeutic areas: CardiovascularRare Diseases
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on EdgeWave.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EdgeWave.

Explore the full profile